A new EFT for cancer immunotherapy

If you know a bit about the biopharma sector, you must know that right now the hottest area is nothing but cancer immunotherapy. BMS is the leading and first company to market the immunotherapy for melanoma, ipilimumab, which has been very successful and profitable. This is really a breakthrough, opening a totally new era for cancer treatment and has brought up the true hope that some day, cancers will not be a fatal disease but rather a chronic one and potentially curable.  Needless to say, a lot of money will be made in this area and this is just a beginning at the moment. I have been hoping for a ETF so that one can have a focused investment with good diversification to minimize the risk. Now we have got one. A brand new EFT, the Loncar Cancer Immunotherapy ETF (CNCR) has just been lunched for about a week. Here is some information for CNCR. It currently includes 35 companies involved in developing various immunotherapies at different stages. It covers both big biopharmas as well as mid-size biotechs. Below is some key portfolio information for CNCR. Given many of the underlying companies are greatly loved by the Street, valuation-wise, CNCR is not cheap. But since this is really one of the hottest areas at the moment, I'm not sure you can expect it to be cheap in the foreseeable future. Using dollar cost averaging may be the best approach to put some money into it. I personally have a high hope for it long-term.